T2SARS-CoV-2 Panel
Awarded Emergency Use Authorization (EUA) by the FDA
LEARN MORE

"Direct detection of SARS-CoV-2 from upper respiratory samples. The panel is commercially available and has been validated in accordance with Emergency Use Authorization requirements from the FDA. The Panel is being distributed in accordance with the FDA guidance on Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). "

T2SARS-CoV-2 Panel
Awarded Emergency Use Authorization (EUA) by the FDA
LEARN MORE

"Direct detection of SARS-CoV-2 from upper respiratory samples. The panel is commercially available and has been validated in accordance with Emergency Use Authorization requirements from the FDA. The Panel is being distributed in accordance with the FDA guidance on Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)."

T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."

– US CMS FY 2020 inpatient prospective payments system final rule
T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"Direct detection of SARS-CoV-2 from upper respiratory samples. The panel is commercially available and has been validated in accordance with Emergency Use Authorization requirements from the FDA. The Panel is being distributed in accordance with the FDA guidance on Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised). "

– US CMS FY 2020 inpatient prospective payments system final rule

T2 could save lives – bottomline.

Now, hospitals can detect and identify sepsis-causing pathogens faster and more accurately.

Hospitals trust in T2MR Technology

UPMC
Demonstrated 47% reduction in antifungal therapy.
Henry Ford Health System
Realized 7 days reduction in median length of stay in the ICU.
Lee Health
T2Bacteria positive results 20 hours sooner than blood culture.
Huntsville Hospital
Saved ~$280 pharmacy costs per patient.
Robert Wood Johnson Medical School
Identified escalation and de-escalation opportunities in patients tested with T2Candida.
Riverside Community Hospital
100% of patients who tested positive received appropriate therapy in <9 hours

Patient Case Studies

Real stories about how T2 Biosystems could have potentially changed clinical practice and patient outcomes.

Secondary Candidemia in Critically Ill COVID-19 Patient

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Case Study 1

53-year-old immunocompromised, female with recent surgery to drain an intra-abdominal abscess

Case Study 2

25-year-old female with cerebral palsy diagnosed with duodenal pneumatosis

Case Study 3

73-year-old female with lymphoma on chemotherapy and diagnosed with pneumonia and septic shock
Previous
Next

Numbers don't lie.

Sepsis contributes to

1 in 5
US hospital deaths.

Sepsis kills

~11 million
people worldwide annually.

Cost of sepsis

$41 billion
in US healthcare costs
Integrate T2 Biosystems panels into your hospital today!

Stewardship Case Studies